From: Neoadjuvant treatment of melanoma: case reports and review
 | Patients (n) | Study design, end point | Agent | Clinical response | Survival |
---|---|---|---|---|---|
Sasson et al. [5] | 16, metastatic | Retrospective, OS | Various* | 62.5% (7PR, 3CR) | OS – 68.8% DFS – 62.5%, median f/u 35 mo |
Jouary et al. [6] | 13, metastatic | Retrospective, OS | DTIC | 60% did not progress. | OS - 31.6 vs 25.3 mo (study group vs. retrospective cohort) |
Shah et al. [7] | 19, Stage III | Phase II, ORR | Tem | 16% (1PR, 2CR) | NR |
Buzaid et al. [8] | 64, Stage III | Phase II, ORR | Cis, Vin, IL2, DTIC, IFN | 50%**(28PR, 4 CR) | Median OS 27 mo. Median DFS 13 mo |
Gibbs et al. [9] | 48, Stage III | Phase II, ORR | Cis, Vin, IL2, DTIC, IFN | 38.9%# (13PR, 1CR) | 79% OS, 65% PFS at 2.6 yrs. |
Koyanagi et al. [10] | 63, Stage III | Phase II, DFS | Cis, Vin, DTIC, IL2, IFN | NR | DFS- 70%, median f/u 30.4 mo. 2 yr OS – 80.9% |
Lewis et al. [11] | 92, Stage III | Phase II, OS | Cis, Vin, DTIC, IL2, IFN | 26%## | RFS – 64% OS- 78%, median f/u 40.4 mo |
Kounalakis et al. [12] | 153, Stage III | Retrospective, OS | Cis, Vin, DTIC, IL2, IFN | 55% + (14 PR, 14 CR) | 5 yr OS-82% (micromet disease), and 77% (bulky disease) |
Moschos et al. [13] | 20, Stage III | Phase II, ORR | HDI | 55% (8PR, 3 CR) | 90% PFS at 1.5 yrs. |